Abstract
This Health Industry Insights report examines the current and future
applications of molecular imaging (MI) in clinical drug development and
identifies areas in which technological advances will increase and broaden the
clinical use of MI.
Noninvasive molecular measurements are becoming an integral part of rational
decision making in the clinical evaluation of promising new drugs. MI
techniques such as MRI, PET, CT, SPECT, ultrasound, and optical imaging are
increasingly being used to connect evaluation of the molecular target in the
lab to the metabolism of the compound in the body. MI offers a new level of
understanding of how drug development candidates directly affect specific
biological processes within the human body, providing insights early in the
drug development process.
With increasing information, however, comes increasing complexity in both
instrumentation and subsequent analysis. Through better knowledge-based drug
development, MI is expected to make the pharmaceutical development more
efficient and more productive.
"Noninvasive molecular imaging promises to transform the drug development
process by providing direct visualization of the specific interactions of new
drugs (both good and bad) within the human body," said Alan Louie, Ph.D.,
research director responsible for Health Industry Insights' research on
technology solutions for drug discovery.
Table of Contents
- Table of Contents
- Health Industry Insights Opinion
- In This Report
- Situation Overview
- Introduction
- Value Proposition for Molecular Imaging
- Imaging Applications in Clinical Trials
- Table: Application of Molecular Imaging in Clinical Trials
- Table: Molecular Imaging Targets for Specific Therapeutic Areas
- Table: Uses of Imaging Technologies for Clinical Compound Evaluation
- Table: Benefits and Limitations of Specific Imaging Technologies
- Imaging in the Clinical Environment
- Magnetic Resonance Imaging (MRI or MR)
- Functional MRI (fMRI)
- Computed Tomography (CT, CAT, or Cat Scans)
- Figure: Algorithmic Construction of Anatomical Images
- Positron Emission Tomography (PET)
- Single Photon Emission Computerized Tomography (SPECT)
- Ultrasound Imaging
- Optical Imaging
- Fusion Modalities
- Technology/Vendor Market Landscape
- Figure: Preclinical Imaging Systems Vendor Landscape
- Figure: Worldwide Imaging Market Share by Modality, 2005
- Figure: Worldwide Imaging Revenue Share by Segment, 2005
- Table: Molecular Imaging System Vendors in the Emerging Preclinical Area
- Clinical Instrument Vendor Landscape
- GE Healthcare
- Siemens Medical Solutions
- Philips Medical Systems
- All Three
- MI Contrast Agent Landscape
- Table: Selected Vendors and Products of Molecular Imaging Contrast Agents
- CRO Imaging Landscape
- Table: Selected Imaging CROs
- Government Efforts to Accelerate MI Adoption
- MI and the NIH Roadmap for Medical Research
- FDA and the Critical Path
- NCI Imaging Efforts
- Figure: NCI Cancer Imaging Programs Detailed Funding, FY96-FY03
- Pharmaceutical Industry Adoption of MI in Clinical Trials
- Factors Affecting the Wider Adoption of MI in Clinical Trials (and in the Hospital)
- Imaging Technology Considerations
- Contrast Agent Considerations
- Infrastructure Considerations
- Regulatory Considerations
- Select New Technology Applications in Molecular Imaging
- Future Outlook
- Rapid Growth Expected in the Imaging Market
- Table: U.S. Molecular Imaging Instrumentation Revenue, 2004-2009 ($M)
- Table: Worldwide and U.S. Molecular Imaging Contrast Agent Sales Revenue, 2003-2009 ($M)
- Essential Guidance
- Actions to Consider
- Specific Recommendations for Pharmaceutical and CRO R&D Management
- Learn More
- Related Research
- Synopsis
|
